These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 37083148)

  • 1. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
    Gaudet V; Yap B; Hassan S; Barbeau M
    J Cutan Med Surg; 2023; 27(3):226-235. PubMed ID: 37083148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
    Rigopoulos D; Tampouratzi E; Angelakopoulos C; Apalla Z; Barkis I; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Chasapi V; Sfaelos K; Ioannides D;
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):1121-1130. PubMed ID: 38308561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
    Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
    Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest.
    Schaeffer L; Ben-Anaya N; Sorbe C; Rustenbach SJ; Mrowietz U; Augustin M
    J Dermatolog Treat; 2024 Dec; 35(1):2340107. PubMed ID: 38636941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.
    Gkalpakiotis S; Kojanová M; Fialová J; Cetkovská P; Vašků V; Vantuchová Y; Machovcová A; Gkalpakioti P; Hrdá P; Arenberger P
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):115-130. PubMed ID: 38032433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of moderate to severe psoriasis with brodalumab-Real-world evidence from the LIBERO study.
    von Kiedrowski R; Hinz T; Mauer G; Schwinn A; Timmel A; Hutt HJ; Augustin M
    J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38572773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived quality of life in patients with psoriasis treated with interleukin 17 and 23 inhibitors.
    Anguita-Montenegro B; Areas-Del Águila VL; Palacios-Moya E; García-Arpa M; Sánchez-Caminero MP; Luque-Jiménez M
    Farm Hosp; 2024; 48(5):204-211. PubMed ID: 38423945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Translated article] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors.
    Anguita-Montenegro B; Águila VLA; Palacios-Moya E; García-Arpa M; Sánchez-Caminero MP; Luque-Jiménez M
    Farm Hosp; 2024; 48(5):T204-T211. PubMed ID: 38897834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date.
    Galluzzo M; D'Adamio S; Massaro A; Piccolo A; Bianchi L; Talamonti M
    Clin Cosmet Investig Dermatol; 2019; 12():311-321. PubMed ID: 31118733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort.
    Caldarola G; Galluzzo M; Bernardini N; Botti E; De Luca E; De Simone C; Mariani M; Moretta G; Pallotta S; Campione E; Peris K
    Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020.
    Lazaridou E; Kourlaba G; Ravanidis S; Gounelas G; Stefanou G; Tsolakidis A; Mathioudakis K; Apalla Z
    Clin Exp Dermatol; 2024 Jul; ():. PubMed ID: 38970536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
    Sood S; Rimke A; Rankin BD; Abduelmula A; Georgakopoulos JR; Maliyar K; Bagit A; Leung F; Stark LA; Devani AR; Vender R; Yeung J; Prajapati VH
    J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885841
    [No Abstract]   [Full Text] [Related]  

  • 13. Author Correction: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
    Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
    Sci Rep; 2024 Mar; 14(1):7144. PubMed ID: 38532006
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
    Sahuquillo-Torralba A; Hospital-Gil M; Vilarrasa-Rull E; Llamas-Velasco M; Rivera R; Carrascosa JM; de la Cueva-Dovao P; Armesto-Santos S; Ruíz-Villaverde R; Velasco-Pastor M; Magdaleno-Tapial J; Yanguas-Bayona JI; Ribera-Pibernat M; Salgado-Boquete L; Herranz-Pinto P; Romero-Mate A; Martínez-Lorenzo E; López-Estebaranz JL; Ballescá-López F; Botella-Estrada R
    Australas J Dermatol; 2023 Nov; 64(4):e317-e326. PubMed ID: 37435962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
    Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
    J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
    Mastorino L; Cariti C; Susca S; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Quaglino P; Ribero S
    Exp Dermatol; 2023 Sep; 32(9):1591-1594. PubMed ID: 37395012
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Kuwahara A; Mieno M; Ohtsuki M
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1347-1360. PubMed ID: 37204609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis.
    Elgaard CDB; Iversen L; Hjuler KF
    Drugs R D; 2023 Jun; 23(2):155-163. PubMed ID: 37155121
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.